GT Biopharma Inc (GTBP) Stock Analysis

Verdict: AVOID

Massive share dilution and rapid cash burn offset Phase 1 TriKE clinical progress, making survival dependent on toxic preferred equity.

Investment score: 19/100

Analysis as of

Is GT Biopharma Inc stock worth reviewing? The TradeMates thesis

The TradeMates model assigns an investment score of 19/100 and recommends AVOID for GTBP. Despite Phase 1 progress in its NK-cell engager pipeline, aggressive share dilution and toxic preferred financing structures erode common shareholder value.

7-factor investment score

GT Biopharma Inc opportunities and risks

What speaks for GTBP

What speaks against GTBP

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
GTBPn/a0.0xn/a0.0%0.0%-211.3%
CNSYn/a3.1xn/a89.6%-620.7%-179.4%
CLRBn/a0.0x0.9x0.0%0.0%-161.0%
AEONn/a0.0xn/a0.0%0.0%-113.9%
PASGn/a0.0x0.4x0.0%0.0%-290.0%
BIVIn/a0.0xn/a0.0%0.0%-173.9%
Peer mediann/a0.0xn/a0.0%0.0%-173.9%

Frequently asked questions about GT Biopharma Inc (GTBP)

Is GTBP stock a good investment?

The TradeMates model rates GT Biopharma Inc as AVOID with an investment score of 19/100. The TradeMates model assigns an investment score of 19/100 and recommends AVOID for GTBP. Despite Phase 1 progress in its NK-cell engager pipeline, aggressive share dilution and toxic preferred financing structures erode common shareholder value. This is algorithmic model output, not personal investment advice.

Is GTBP stock a buy?

The TradeMates model verdict for GTBP is AVOID with an investment score of 19/100. Treat this as a model signal to review, not a personal buy recommendation.